



14th International Workshop

Multiple Endocrine Neoplasia

and other rare endocrine tumors

September 25 – 27, 2014

Vienna - Austria

Congress Venue

Gesellschaft der Ärzte in Wien - Billrothhaus
Frankgasse 8, A-1090 Wien

www.worldmen2014.at

International Scientific Committee

(alphabetical order)

A. Beckers (Belgium)
J. Bertherat (France)
M.L. Brandi (Italy)
H. Dralle (Germany)
R.F. Gagel (USA)
S.J. Marx (USA)
B. Niederle (Austria)
F. Raue (Germany)
B.G. Robinson (Australia)
C.A. Stratakis (USA)
R.V. Thakker (United Kingdom)
B. Wiedenmann (Germany)

Local Organising Committee (Austria)

B. Niederle, Vienna – Chairman

C. Scheuba, Vienna – Vice Chairman

C. Bichler, Vienna

P. Riss, Vienna

A. Selberherr, Vienna

St. Strobl, Vienna

National Delegates Committee (Austria)

S. Baumgartner-Parzer, Vienna

O.A. Haas, Vienna

A. Luger, Vienna

V. Stepan, Graz

I. Virgolini, Innsbruck

Jakob Erdheim (1874–1937) reported a necropsy case of a pituitary adenoma and enlarged parathyroid glands in 1903 - the first published case of Multiple Endocrine Neoplasia 1

Erdheim J.

Zur Normalen und Pathologischen Histologie der Glandula Thyroidea, Parathyroidea und Hypophysis. Beitr z Path Anat u z Allg Path 1903;33:158–236)

The international workshop “WorldMEN2014” is dedicated to this very famous Austrian pathologist!

Scientific Program

Thursday, September 25, 2014

08:00 – 16:00		Arrival in Vienna	
16:00 – 17:45		Session 1 Genetic aspects of pituitary tumors	
	Chair		M.L. Jaffrain-Rea (Italy)
	Chair		A. Daly (Liège)
	Chair		A .Luger (Austria)
S1.1	15 min (10+5)	Clinical and genetic aspects of familial isolated pituitary adenomas	A. Beckers (Belgium)
S1.2	15 min (10+5)	How <i>AIP</i> mutations cause aggressive pituitary adenomas (cancelled)	A. Karhu (Finland)

S1.3	15 min (10+5)	Micro-RNAs in pituitary adenoma pathology: culprits or bystanders?	M.C. Zatelli (Italy)
S1.4	15 min (10+5)	Pituitary gland in MEN1 syndrome: from histo-pathology to prognosis	C. Villa (France)
S1.5	15 min (10+5)	Clinical features and therapeutic outcomes in aggressive pituitary adenomas and carcinomas	G. Raverot (France)
S1.6	15 min (10+5)	What we know and don't know about the pathophysiology of MEN 1 pituitary adenomas	S. Agarwal (USA)
FP1.1	10 min (7+3)	Absence of GNAS1 mutations in somatotropinomas from AIPmut positive patients: possible implications for phenotype.	Marta Korbonits (United Kingdom)
17:45 – 20:00		Opening Ceremony Welcome Reception and Poster Party	
	17:45 – 18:15	Opening Ceremony	
	18:15 – 20:00	Welcome Reception / Poster Party	

Friday, September 26, 2014

08:00 – 09:50		Session 2 MEN 1 and hyperparathyroid syndromes	
	Chair		R.V. Thakker (United Kingdom)
	Chair		M.L. Brandi (Italy)
	Chair		O.A. Haas (Austria)
S2.1	5 min	Introduction FIRMO Parathyroid Medal to E.M. Brown	M.L. Brandi (Italy)
S2.2	25 min (20+5)	The calcium sensing receptor (CaSR) and disordered of Ca ²⁺ -sensing: from the gene to the patient	E.M. Brown (USA)
S2.3	20 min (15+5)	Genetics of parathyroid tumors	R.V. Thakker (United Kingdom)
S2.4	20 min (15+5)	Medical Management of primary hyperparathyroidism	M.L. Brandi (Italy)

S2.5	20 min (15+5)	Management of primary hyperparathyroidism in pregnancy: why and when?	R. Eastell (United Kingdom)
FP2.1	10 min (7+3)	Treatment of children with Neonatal Severe Hyperparathyroidism (NSHPT)	T.R. Kurzawinski (United Kingdom)
S2.6	10 min (7+3)	Hyperparathyroidism - Jaw Tumor Syndrome: current aspects in diagnosis and treatment	M. Iacobone (Italy)
09:50 -10:20		Historical Lecture	
L1.1	5 min	Introduction	B. Niederle (Austria)
L1.2	20 min	Jakob Erdheim (1874-1937) – pioneer of endocrine pathology	H. Swoboda (Austria)
10:20 - 10:40		Coffee break	

10:40 – 12:40		Session 3 MEN 1 and the pancreas	
		Under the auspices of the European Society of Endocrine Surgeons (ESES)	
	Chair		H. Dralle (Germany)
	Chair		M. Falconi (Italy)
	Chair		G. Akerström (Sweden)
S3.1	15 min (10+5)	Indication for surgery in MEN1 neuroendocrine pancreatic tumors: Biology	A. Perren (Switzerland)
S3.2	15 min (10+5)	Indication for surgery in MEN1 neuroendocrine pancreatic tumors: Size	F. Triponez (Switzerland)
S3.3 + FP3.1	15 min (10+5)	Indication for surgery in MEN1 neuroendocrine pancreatic tumors: Molecular genetic aspects	J. Waldmann (Germany)
FP3.2	10 min	Should 68Gallium-DOTATATE PET/CT be the first-line imaging study	S. Sadowski

	(7+3)	to detect neuroendocrine tumors in patients with multiple endocrine neoplasia type 1?	(USA)
S3.4	15 min (10+5)	Resection (Thompson procedure) or total pancreatectomy, asymptomatic tumors	G. Doherty (USA)
S3.5	15 min (10+5)	Surgical concepts of MEN1 gastrinoma	D.K. Bartsch (Germany)
S3.6	15 min (10+5)	Clinical features and surgical management of MEN1 insulinomas	F. Tonelli (Italy)
S3.7	15 min (10+5)	Is laparoscopic surgery in patients with neuroendocrine pancreatic tumors associated with multiple endocrine neoplasia type 1 adequate?	L. Fernández-Cruz (Spain)
12:40 – 13:00		Break	

13:00 – 14:00		Lunch Symposium	
		Medical treatment of advanced neuroendocrine pancreatic neoplasia	
		Under the auspices of the European Neuroendocrine Tumor Society (ENETS)	
	Chair		M. Pavel (Germany)
	Chair		K. Öberg (Sweden)
LS1.1	15 min (10+5)	Molecular Subtypes of Pancreatic NETs and their Distinct Phenotypes	A. Sadanandam (United Kingdom)
LS1.2	15 min (10+5)	Somatostatin analogs – what do we learn from the current clinical trials?	M. Raderer (Austria)
		Integration of targeted- therapy into treatment regimens: Sunitinib and Everolimus - Competition or completion	
LS1.3	15 min (10+5)	Sunitinib in the treatment of advanced pancreatic neuroendocrine tumors – current data	E. Raymond (France)

LS1.4	15 min (10+5)	Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience	J.C. Yao (USA)
14:00 – 14:10		Break	
14:10 - 15:00		Session 4 Selected case presentations	
	Chair		C. Scheuba (Austria)
	Chair		C. Bichler (Austria)
CP4.1	10 min (7+3)	Five families with RET-mutation negative familial medullary thyroid carcinoma: what lies beyond RET?	D. Iacovazzo (United Kingdom)
CP4.2	10 min (7+3)	Are cystic parathyroid adenomas in MEN1 related to cinacalcet treatment?	T. Cavalli (Italy)
CP4.3	10 min (7+3)	A case report of the youngest-ever reported malignancy in multiple endocrine neoplasia type 1	M. Lewis (USA)
CP4.4	10 min (7+3)	Maxillary myxomas associated with MEN1 syndrome	D. Lourenço (Brazil)
CP4.5	10 min	Interdisciplinary treatment of a high malignant gastric neuroendocrine	F. Watzka

	(7+3)	carcinoma (NEC) with hepatic metastasis in multiple endocrine neoplasia type I syndrome: a case report	(Germany)
15:00–15:25		Jakob Erdheim Honorary Lecture	
L2.1	5 min	Introduction	B. Niederle (Austria)
L2.2	20 min	Monoclonality, polyclonality, and coupling in MEN1 and other endocrine tumors	S.J. Marx (USA)
15:25-15:30		Break	
15:30 -17:30		Session 5 MEN 2 and rare RET mutations/ Medullary thyroid cancer	
	Chair		F. Raue (Germany)
	Chair		S. Baumgartner-Parzer (Austria)
		The clinical case discussion	TED - 1
S5.1	5 min	Clinical data	F. Raue (Germany)

		Diagnostic perspectives	
S5.2	10 min (7+3)	Cytological, biochemical and molecular findings	R. Elisei (Italy)
S5.3	10 min (7+3)	Functional Imaging	G. Treglia (Switzerland)
		Treatment perspectives	
S5.4	15 min (10+5)	Surgical perspectives	H. Dralle (Germany)
S5.5	10 min (7+3)	Medical perspectives (see also S7.2)	F. Raue (Germany)
	10 min	Discussion	TED – 2
S5.6	15 min (10+5)	New developments in the guidelines for management of MEN 2 and medullary thyroid carcinoma	K. Frank-Raue (Germany) S. A. Wells (USA)
FP5.1	10 min (7+3)	Hereditary medullary thyroid cancer, a comparative study in a Spanish reference care center	I. Crespo Hernandez (Spain)

FP5.2	10 min (7+3)	Long term parathyroid function following total parathyroidectomy with autotransplantation in adult patients with Multiple Endocrine Neoplasia (MEN)	T. Imai (Japan)
FP5.3	10 min (7+3)	Medullary Thyroid Carcinoma in patients with MEN 2B in Norway. Clinical course of an orphan disease	E.M. Opsahl (Norway)
FP5.4	10 min (7+3)	Intronic changes in our patients with Medullary Thyroid Carcinoma MTC	B. Peric (Slovenia)
17:30–17:50		Coffee break	
17:50-19:00		Session 6 New experimental and clinical developments	
	Chair		S.J. Marx (USA)
	Chair		I. Virgolini (Austria)
S6.1	15 min (10+5)	Nuclear RET Increases Survival by Suppression of ATF4-mediated Apoptosis	R. Yarmand (USA)
S6.2	15 min	Molecular profiling of intestinal NET: future application	M.S. Banck

	(10+5)		(USA)
S6.3	10 min (7+3)	Epigenetic regulation of Hedgehog signaling in MEN1 tumor syndrome.	X. Hua (USA)
FP6.1	10 min (7+3)	Chemoprevention with Enalapril and ASS prolongs survival through the AT1-Receptor and NFkB in a transgenic mouse model for islet cell tumors	Jens Waldmann (Germany)
FP6.2	10 min (7+3)	Gender-related differences in MEN1 lesion: analysis of 560 cases from the database of the MEN Consortium of Japan	M. Katai (Japan)
20:00		Evening Event	

Saturday, September 27, 2014

08:00-10:00		Session 7	
		Treatment of advanced endocrine tumors	
	Chair		B. Wiedenmann (Germany)
	Chair		B. Eriksson (Sweden)
S7.1	20 min (15+5)	Treatment landscape of NET	M. Pavel (Germany)
FP7.1	10 min (7+3)	Streptozocin and 5-fluorouracil treatment of pancreatic neuroendocrine tumors: efficacy, toxicity and prognostic factors	B. Eriksson (Sweden)
		Advanced medullary thyroid carcinoma: Integration of tyrosine kinase therapy into treatment regimens Vandetanib and Cabozantinib – Competition or completion	
S7.2	15 min (10+5)	Vandetanib - Current perspectives	S. A. Wells (USA)

S7.3	15 min (10+5)	Cabozantinib - Current perspectives	R. Elisei (Italy)
FP7.2	10 min (7+3)	Treatment with sorafenib in progressive metastatic medullary thyroid cancer (MTC) is well tolerated and is associated with symptom and tumor control	L.A. Castroneves (Brazil)
S7.4	20 min (15+5)	Current aspects of a personalized treatment approach in advanced adrenocortical cancer	J. Bertherat (France)
FP7.3	10 min (7+3)	Paraganglioma and pheochromocytoma: A difference in disease behaviour and clinical outcomes	T. Ezzat Abdel-Aziz (United Kingdom)
10:00-10:30		Coffee break	
10:30-11:30		Session 8 Selected poster presentation	
	Chair		P. Riss (Austria)
	Chair		A.Selberherr (Austria)
SP8.1	10 min (7+3)	Culture of human neuroendocrine tumor cells and xenografts - old and new problems	R. Pfragner (Austria)

SP8.2	10 min (7+3)	The CYS634ARG (C634R) mutation provides more aggressiveness to the MEN 2A syndrome	J. Rodriguez (Spain)
SP8.3	10 min (7+3)	Follow-up of ≤ 2 cm non functioning pancreatic NETs in patients with MEN1 treated with conservative approach	M.V. Davi' (Italy)
SP8.4	10 min (7+3)	Characteristics of 'foregut' carcinoid tumours occurring in multiple endocrine neoplasia type 1 (MEN1)	L. Yang (United Kingdom)
SP8.5	10 min (7+3)	Potential benefits of a multinational patient alliance to patients with MEN	J. Grey (United Kingdom)
SP8.6	10 min (7+3)	Breast cancer predisposition in multiple endocrine neoplasia type 1 (see abstract "P10")	K. Dreijerink (USA/The Netherlands)
11:30-13:30		Session 9 Hereditary pheochromocytoma and paraganglioma	
	Chair		B.G. Robinson (Australia)
	Chair		C.A. Stratakis (USA)
	Chair		V. Stepan

			(Austria)
S9.1	20 min (15+5)	Carney-Stratakis dyad and Carney Triad: an update	C.A. Stratakis (USA)
FP9.1	10 min (7+3)	Definition of a new algorithm for molecular-genetic testing of patients with hereditary pheochromocytoma and paraganglioma syndromes	T. Musholt (Germany)
S9.2	15 min (10+5)	The role of imaging in screening for pheochromocytoma and paraganglioma	R. Hicks (Australia)
S9.3	15 min (10+5)	Clinical experience from the French paraganglioma network (PGL.EVA study)	Ch. Lepoutre (France)
S9.4	15 min (10+5)	A new paraganglioma-polycythemia syndrome: Clinical presentations, genetics, and pathogenesis	K. Pacak (USA)
S9.5	15 min (10+5)	Malignant hereditary pheochromocytoma and paraganglioma: focus on therapeutics	E. Baudin (France)
FP9.2	10 min (7+3)	Validation of immunohistochemistry for SDHB in assessment of germline mutations in pheochromocytoma/paraganglioma (PGG/PCC) syndrome	J. Ares (Spain)
13:30-14:00		Closing Ceremony Poster award/Best presentation award	